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Abstract
Synthetic sling surgery is the procedure of choice for surgical correction of
stress urinary incontinence (SUI) in females. However, complications do
occur, and may require surgical intervention to treat them in some instances.
In a retrospective study we identified and analyzed those complications to
determine their incidence and associated predictive factors. A total of 59,887
women who had synthetic sling procedure were included. Incidence of
surgically treated complications was 2.2 % ((95% CI 2.07- 2.30) and at 10
years follow up cumulative incidence rate was 3.3% (95% CI 3.0- 3.5).
There was no significant difference in complication rate between urologists
versus gynecologists. A significant reduction in complications was noted
with high surgical volume providers (HR 0.73, 95% CI 0.65-0.83). Patient’
factors like age and simultaneous surgeries had significant effect. Results
support the Food and Drug Administration recommendation about use of
synthetic meshes and slings in vaginal surgery.

Keywords
Synthetic /mesh slings, Sling Revision, Stress Urinary Incontinence,
Predictive Factors
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1 Introduction

Stress urinary incontinence (SUI) is considered a common condition in
women with considerable socioeconomic impacts. Depending on its
severity, therapeutic options differ. Surgical intervention with urethral slings
is currently the procedure of choice for SUI correction in females (1).
However, complications are well documented and necessitate removal or
release some-times. In this thesis, we will demonstrate the results of a
retrospective study in which the incidence of SUI surgery in women was
measured and rate of surgically treated post sling complications were
documented. Factors that might influence complications were also identified
and discussed in view of statistics and literatures.

1.1

Stress Urinary Incontinence (SUI) in females

Stress urinary incontinence (SUI) in females is a common condition. It’s
considered to be symptom, sign and clinical disease. It is defined as
“symptomatic complaint of involuntary leakage of urine on effort or
exertion, and it can be noted in urodynamic study (UDS) as involuntary
leakage of urine during increases in abdominal pressure in the absence of a
detrusor contraction—so-called urodynamic stress incontinence” (2).
Literature shows variable percentages of women affected by SUI, likely due
to inconsistencies in definitions used by different investigators, which give a
percentage between 15- 80% of women suffering from SUI (2).

1.1.1 Pathophysiology of SUI
Pathophysiology of SUI in females was studied and reviewed as early as 19th
century (Sinclair AJ). At that time anatomic theories were postulated to
understand and diagnose incontinence. Textbooks of that era reflected such
opinions, and in an old gynecology book the author hypothesized that “the
cause… is usually a prolapse of the anterior vaginal wall” and “incontinence
is also of common occurrence” (3).
With advancement in technology and diagnostic tools in the early 20th
century, a deeper understanding of pathophysiology of SUI was achieved
and different theories evolved. The pressure transmission theory and
sphincteric dysfunction theory were proposed and examined with repeated
modifications over time (4). Currently, female SUI is thought to be the result
of the combination of urethral hypermobility and intrinsic sphincteric
dysfunction (ISD) (2). When intra-abdominal pressure increases due to
cough or any other strenuous activity, the posterior wall of the urethra moves
away from the anterior urethral wall. This causes opening of bladder neck
due to urethral hypermobility, and leads to a loss of urine. ISD however,
arises from defects within the urethra proper itself, so that the urethral
sphincter is unable to close properly and generate enough resting urethral
closing pressure to hold urine in the bladder (2).
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1.1.2 Classification of SUI
Classification of SUI was proposed and modified by several investigators
since 1920s (4). Blaivas and Olsson modified a classification system
proposed by McGuire and colleagues (Table 1.1). This system was founded
based on the position of the vesical neck in relation to symphysis pubis and
it’s descent during increase intra-abdominal pressure (diagnosed while
imaging with fluoroscopy). It also monitors the integrity of the intrinsic
sphincter mechanism (4).
Table 1.1 Classification of Urinary Incontinence by Blaivas and Olsson
Classification

Finding at Rest

Finding during Cough

Type 0

Flat bladder above

Rotational descent of urethra and

symphysis pubis

bladder base; no urine leakage

Flat bladder base above

Bladder base descends less than 2 cm

inferior margin of

in relation to pubis; bladder neck and

symphysis pubis

urethra both open with leakage

Flat bladder base above

More then 2 cm descent of bladder

inferior margin of

and urethra below pubis; urethra open

symphysis pubis

with leakage

Flat bladder base at or

More descent and rotation of bladder

below inferior margin of

and urethra below pubis; urethra open

symphysis pubis

widely with leakage

Bladder base rests above

Bladder base above or below

symphysis pubis; bladder

symphysis pubis; both bladder neck

neck and urethra are open

and urethra are open

Type I

Type IIA

Type IIB

Type III
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1.1.3 Management of SUI
SUI has a significant life impact on patient in multiple aspects, and
depending on the degree of incontinence and patient’s coping strategies this
impact can range between mild anxiety and fear of public activities to a full
blown condition of depression and social isolation. Several areas of life can
be affected such as social activities, physical performance and sports, sexual
relationships, and even sleep may be affected (3). It is very important to
consider and evaluate SUI impact on patient’s life and follow it through out
the treatment period.
Depending on severity of the condition, together with other patient factors,
therapeutic options for SUI in women widely differ. Non-surgical
intervention is well-established and recommended as first line therapy for
urinary incontinence (UI) in form of behavioral (e.g. pelvic floor muscle
rehabilitation) and pharmacological therapy (e.g. tricyclic antidepressant
agent) (2). Such treatment modalities usually need high level of motivation
and long-term commitment by patients. Surgical intervention aims to
improve support to urethrovesical junction and strengthen all mechanisms
contributing to continence. Different surgical methods have been described
with variable success rates (2). Usually it’s the surgeon’ preference and
training that play the most important role in choosing type of anti
incontinence surgery. Other factors also contribute to the decision like the
anatomical nature of incontinence and general health condition of the
patients.
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1.2

Sling Surgery for SUI

Urethral sling surgery is currently the procedure of choice for SUI with a
variety of techniques and materials (2). It’s routinely performed vaginally or
abdominally (open or laparoscopic). In 2004, access through obturator
foramen was described. Different materials have been consumed for sling
fashioning, like autologous, allograft, xenograft, and synthetic materials.

1.2.1 History of Sling Surgery
Von Giordano first introduced the concept of sling surgery in 1907 as he
used gracilis muscle graft wrapped around urethra (2). Frangenheim used
rectus abdominis muscle and fascia in 1914, then, Millin adapted it for use in
recurrent SUI (2). In 1933, Price used fascia lata to treat urinary
incontinence in women with sacral agenesis, and he fixed it to the rectus
muscle (5). Aldridge in 1940s described the use of paired strips of rectus
fascia to form a sling and sutured them below the urethra (2). In 1970s,
McGuire used the pubovaginal sling (PVS). He placed it at the bladder neck
to correct urethral hypermobility and decrease the pressure transmission due
to intra-abdominal pressure changes (2). First, it was used in patients who
failed previous retropubic suspension procedures, and had a cure rate of
91%, which was why this procedure was reintroduced. Zaccharin in the
1960s and DeLancey in the 1990s hypothesized competing theories in which
the role of pubourethral ligaments in maintaining urinary control was
emphasized (2). They also stressed the role of midurethral mechanism in
maintaining urinary continence under stress conditions (2). In 1990s,
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Ulmsten described his midurethra theory, (previously known as integral
theory), and it’s first formulation was published in 1990 (6):
“For different reasons, stress and urge derive mainly from laxity in the
vagina or it’s supporting ligaments, a result of altered collagen/elastin”
Ulmsten postulated that injury due to different reasons such as surgery,
aging, and parturition lead to weakening of the pubourethral ligaments. This
affects the midurethral and anterior urethral wall support, which results in
urinary incontinence (2). Radiological investigations later on provided a
higher level of proof, and ultrasound technique brought a deeper
understanding of vesicourethral dynamics after placement of sling (2) (6),
which even further improved the understanding of continence mechanism in
view of midurethra theory. Using those theories, the concept of mid urethral
sling was developed, and since then, different approaches evolved with
different materials and different suspension/fixation techniques.

1.2.2 Different Materials of Slings
Slings have been fashioned from various substances. A broad classification
categorizes those substances to: autologous, allograft, xenograft, or synthetic
materials. Ideally, sling material should be easily integrated into the host
with the least tissue reaction, promote organized fibrosis, and be compatible
with tissues (2).
Autologous slings were used in the late twenty-century. The most common
material used currently is rectus fascia. A pronounced benefit of this type of
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material is the lack of tissue reaction, which decrease risk of erosion
significantly (7). Studies suggest that when autologous fascia is implanted
there is a minimal to moderate inflammatory response, a moderate degree of
collagen production, and a considerable degree of graft remodeling over the
long term with reported rate of cure over 90% (7). However, such surgical
approach increases operative time, prolongs recovery period post operatively
with relative increase in pain, and limits the supply of the sling material.
Also, the fact that another wound site is created for harvesting the sling adds
to autologous disadvantages. Yet, they are considered to be the most
successful biological material used in contemporary SUI surgery (7).
When allograft materials are used as SUI-slings, operative time decreases
and the harvest wound is eliminated. Currently, allograft slings are derived
from cadaveric fascia late or acellular human dermis. Before it’ s implant,
allografts undergo a long process of cleaning, sterilization and occasionally
radiation to eradicate infective organisms and eliminate genetic materials
before it is implanted (2) (7). Several studies evaluated changes in the
mechanical properties of allografts after implantation, and results were
mixed (7), however, histologic analysis revealed cadaveric dermis to have
minimal host fibroblast infiltration and little neovascularity with marked
thinning and degradation of the graft (2) (7). This may affect their long-term
success rate. Another concern is low potential of disease transfer due to the
low risk of erosion. There have been no cases reported yet of a disease
transfer after allograft sling implantation, however, cases of HIV and
Creutzfeldt-Jakob disease (CJD) transmission have been reported after
transplantation of other cadaveric tissues (2). Although the risk of disease
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transmission is low, human DNA has been detected in various allograft
materials with an unknown clinical significance (2).
Xenograft has been used since the 1980s with less frequent use in recent
years. Types available for use are porcine dermis or small intestinal
submucosa (SIS) and bovine pericardium. As an allograft, xenograft tissue
undergoes processing techniques in order to make it safer and more pliable
(2). Sometimes, porcine dermis undergoes further crosslinking to make it
more resistant to enzymatic digestion, and when laboratory studies evaluated
mechanical properties and host response to xenograft different results were
retrieved based on the material being cross-linked or not (7). Xenograft has
significant lower tensile strength after implantation, and it has little or no
inflammatory reaction, which results in subsequent limited collagen
remodeling and graft degradation (2) (7). In a randomized multicenter
clinical trial conducted to compare porcine xenograft sling, short autologous
fascial sling and the synthetic tension free vaginal tape (TVT) in stress
incontinence surgery, the re-operation rate for delayed failure of xenograft
slings was significantly worse than both the TVT or fascia (8).
Synthetic slings were introduced for the first time in 1953 and were made of
Nylon (2). Since then, range of synthetic materials have been used in SUI
surgery with Gynecare TVT (Ethicon Women’s Health & Urology,
Somerville, NJ) being the first implantable mesh sling device, and it was
composed of a polypropylene material (9). Synthetic slings have obvious
advantages over all other types of slings: more uniform and consistent, more
durable, unlimited supply of graft material in various sizes and shapes, and
elimination of harvest sites, which consequently positively influences
operative time and post operative pain and recovery. Also, the potential low
8

risk of disease transfer with biological materials is absent in the case of
mesh. Regarding their mechanical properties, synthetic slings are greatly
affected by the physical characteristics of the mesh, such as filament count,
porosity, and polymer molecular weight (7).
In general, mesh stimulates a pronounced degree of inflammation, leading to
massive cell infiltration and ultimate collagen production (2) (7). There is no
degradation of the graft, and the mesh is usually completely infiltrated by the
host tissue.
Significant differences exist between surgical meshes available today, such
as type of material, amount of yarn, and amount of construction (10).
Generally, they are classified into four classes depending on their pores size
(Table 1.2).
Table 1.2 Amid Classification of Surgical Synthetic Materials
Type

Description

Brands

I

Pores > 75 µm
Macroporous
Pores < 10 µm
Microporous
Macroporous with
multifilamentous or
microporous components
Submicronic pore size

Atrium, Trelex, Marlex, Prolene,
Polypropylene
GORE-TEX, Surgical Membrane, Dualmesh

II
III

IV

Teflon, Mersilene, Surgipro, MicroMesh

Silastic, Cellcard

This classification by Amid (1997) was used originally for synthetic
materials in hernia surgery, and it’s applied to urology as well (2). Type I
mesh is totally macroporous, which facilitates its infiltration with
macrophages, blood vessels, and collagen fibers. Type II includes materials
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with pore size less than 10 µm. Type III includes prosthesis that is
macroporous with multifilamentous or microporous components. Lastly,
type IV includes materials with submicronic pore size (2). The most
commonly used synthetic material for SUI slings is propylene mesh, which
is composed of loosely woven strands with pore size greater than 80 µm.
This allows movement of inflammatory cells during initial response and
later on better host tissue ingrowth (2). Different types of synthetic slings
available commercially are explained in Table 1.3.
Table 1.3 Synthetic Sling Different Materials
Trade Name
Mersilene

Composition
Polyethylene terephthalate

Teflon

Polytetrafluroethylene
(PTEF)
Expanded PTFE
Silicone plus woven
polyethylene terephthalate

GOR-TEX
Silastic

ProteGen
Marlex, Prolene

Synthetic mesh with
collagen matrix
Polypropylene

Details
Multifilament fibers, very porous,
firmly embedded in native tissues
Multifilament
Very flexible
Minimal tissue reaction, easy removal
or revision if necessary
Removed from market due to high rate
of vaginal extrusion
Monofilament with open-weave
pattern

In spite all advantages of synthetic slings; serious disadvantages with
variable occurrence rate do exist. Depending on physical properties of the
mesh and the host inflammatory response, histological changes to the
surrounding tissues occur, and might cause genitourinary erosion, vaginal
extrusion or infection (2). Those disadvantages were noted to be more
pronounced if synthetic sling was used as PVS, so it’s not used for this
surgery (2), and more commonly used in a midurethral positioning.

10

1.2.3 Surgical Approaches of Sling Surgery

Different surgical approaches have been described for synthetic sling.
Choosing the specific approach is highly influenced by patient factors and
criteria of her incontinence. One approach that is less commonly used
currently is abdominal approach (5). It’s used mainly when restrictions to
lithotomy position cannot be overcome, or in the rare event of concurrent
sling placement at the time of abdominal surgery. With this approach, the
retropubic space is opened, with a tunnel created under bladder neck and
proximal urethra, then, a sling is passed in that tunnel without vaginal
incision and brought up to either Cooper’s ligament or rectus fascia (5). The
drawback of the abdominal approach is the risk of placing the sling too
distally, which increases the risk of obstruction. Also, there might be a need
to open the bladder to help in the dissection at the bladder neck level (5).

Abdomino-vaginal approach is more common than abdominal only approach
(5). It has the advantage of simultaneous vaginal and abdominal repair when
required. With this technique, accurate placement of the sling under bladder
neck is achieved by dissecting both retropubic space and vaginal wall, with
less dissection required retropubicly (5). Its benefits are markedly apparent
in cases of recurrent SUI in which good access to both anterior vaginal wall
and retropubic space is needed (5).

Vaginal approach is the commonest approach used for sling placement in
SUI surgery. Both PVS and midurethral sling (MUS) are placed through this
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access with help of special needles or introducers. Patient is placed in
lithotomy position, and a longitudinal incision in the anterior vaginal wall is
carried out at the level of bladder neck or midurethra. Depending on the SUI
surgical kit, technique of placing and positioning sling differs. Initially, TVT
was placed via a through vaginal incision through the retropubic space,
(bottom-to-top approach). Later on, retropubic top-to-bottom approach has
been introduced as the suprapubic arc system (SPARC, American Medical
Systems, Inc., Minnetonka, MN, USA). (See Figure 1.1)
Then, a significant modification to the MUS insertion technique was
introduced; the transobturator MUS (TMUS) was designed to avoid the
blind passage of the needle through the retroperitoneal space (11). In this
approach, needle traverses through obturator foramen for fixing the tape.
First, it was inserted in an outside-in technique only, and then a second
technique with an inside-out placement of the sling was described.

Figure 1.1 Vaginal approach in midurethral sling (MUS) placement via retropubic,
bottom-to-top route.
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Figure 1.2 Vaginal approach of midurethral sling (MUS) Placement via
transobturator route.

The vaginal approach continued to have modifications as new sling kits were
developed and marketed. A single-incision sling was developed as a less
invasive procedure with comparable subjective and objective cure rates in
short term follow up. It may have a quicker recovery period and may have a
lower risk of some complications; however, adverse effects like mesh
erosion and urinary retention are not absent (11). Table 1.4 displays different
surgical kits of slings available in the market with their surgical approaches
and techniques.

Table 1.4 Commercial Synthetic Slings Kits
Name

Manufacturer

Technique/Approach

TVT

Ethicon

RMUS bottom to top

TVT-O

Ethicon

TMUS inside to out

TVT-Secure Ethicon

Single incision

SPARC

AMS

RMUS top to bottom

Monarc

AMS

TMUS outside to in

MiniArc

AMS

Single incision
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Name

Manufacturer

Technique/Approach

Advantage

Boston Scientific

RMUS bottom to top

Lynx

Boston Scientific

RMUS top to bottom

ObTryx

Boston Scientific

TMUS outside to in

Solyx

Boston Scientific

Single incision

Aris

Coloplast

TMUS outside to in

Ajust

Bard

Single incision
(Adjustable sling)

1.3

Complications of Sling Surgery

As previously explained, there are different approaches and techniques of
anti incontinence surgery using slings. Complications vary according to
material and approaches.
As our study was to evaluate synthetic sling complications and potential risk
factors, we will focus on complications of synthetic slings in subsequent
discussion.

1.3.1 Classification of Synthetic Sling Complications

Complications in general can be classified to different groups and divisions
depending on time of seeking medical advice, severity of complications, or
site of occurrence of complications. Synthetic sling complications are
significantly related to surgical approaches and/ or technique used in the
surgery. Before we elaborate on such classification, we should display the
14

classification of the complications of meshes and tapes proposed by the
International Urogynecological Association (IUGA) and the International
Continence Society (ICS) Joint meeting in 2010. This classification aimed to
be a basis for a registry of such complications and an aid to clinical practice
and research (12). It categorizes the complications in relation to the insertion
of prostheses and grafts in pelvic floor surgery in females, and it is based on
category (C), time (T) and site (S) classes and divisions, in hopes of
encompassing all possible scenarios for describing insertion complications
and healing abnormalities of those surgeries. It uses numerals and letters
(see Tables 1.5-6). In categories (C), seven divisions were composed to
describe vaginal, urinary tract, rectal or bowel, skin and/or musculoskeletal
and patients’ specific complications. Each category is subdivided into
further classes depending on category’ criteria and description. The second
component of the classification is time (T), which describes the time of
clinical diagnosis of that complication. It has four divisions; the earliest time
might involve insertion issues of the mesh/tape, whilst later divisions are
usually related to healing abnormality issues. The third component of this
classification describes the site (S) of the complication. As one might expect,
possible sites of tape complications are vaginal, trocar passage,
musculoskeletal, and intra-abdominal. One division is entitled as systemic
complications with no specific site.

This classification was hoped to be useful for all parties involved in female
pelvic floor surgeries like anti incontinence procedures and prolapse repair,
including surgeons, physicians, nurses, and industry, so all of them will be
referring to the same clinical issue in consistency. Examples of how this
classification can be applied clinically are illustrated in Table 1.7.
15

IUGA/ICS classification has been evaluated and applied in study conducted
by Petri et al. and results were published in 2012 (13). They studied 376
women with complications of synthetic slings, which were managed
surgically, and after analysis of data, they found that new IUGA-ICS
classification could be applied to most of the types of complications.
However, de novo development of overactive bladder (OAB) was not
included. The study recommended application of this classification in
clinical practice with minor modifications such as inclusion of OAB as a
complication of the synthetic sling surgeries. This recommendation was
based on their review of complication cases in which they found that
development of de novo OAB symptoms was the commonest complication
encountered (13). However, still this classification is not widely adopted by
neither clinical studies nor surgeons involved in management of SUI and/ or
pelvic organ prolapse (POP) repair.
Table 1.5 International Urogynecological Association (IUGA)/International
Continence Society (ICS) Joint Classification of Complications Related Directly to
the Insertion of Meshes in Female Pelvic Floor Surgery: CATEGORY (C)
General

A

B

C

D

Description

(Asymptomatic)

(Symptomatic)

(Infection)

(Abscess)

1 Vaginal

1A

1B Symptomatic

1C

1D

No epithelial

Abnormal graft

(e.g. pain,

Infection

Abscess

separation

finding on

dyspareunia)

2C

2D

Infection

Abscess

3C

3D

Infection

Abscess

examination
2 Vaginal

2A Asymptomatic

2B Symptomatic

Exposure >=
1cm
3 Vaginal

3A Asymptomatic

3B Symptomatic

Exposure < 2cm
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General

A

B

C

D

Description

(Asymptomatic)

(Symptomatic)

(Infection)

(Abscess)

4 Urinary Tract

4A

4B

4C Ureteric or upper

Perforation,

Small

Other LUT

urinary tract complication

fistula, calculus

intraoperative

Complication/

defect (bladder

Retention

perforation)
5 Rectal or

5A

5B

5C

5D

Bowel

Small

Rectal injury or

Small or

Abscess

Perforation,

intraoperative

compromise

large bowel

fistula

defect

injury or
compromise

6 Skin and/ or

6A Asymptomatic,

6B Symptomatic

6C

6D

Musculoskelet

abnormal finding

e.g. discharge,

Infection e.g.

Abscess

al

on examination

pain or lump

sinus tract

discharge, pain,

formation

sinus tract
formation
7 Patient

7A

7B

7C

Compromise

Bleeding

Major degree of

Mortality

like hematoma

complication

resuscitation or
intensive care

Table 1.6 An International Urogynecological Association (IUGA)/International
Continence Society (ICS) Joint Classification of Complications Related Directly to
the Insertion of Meshes in Female Pelvic Floor Surgery: TIME (T) and SITE (S)
TIME
TI

T2

T3

T4

Intraoperative -

48 hours- 2

2 months-

Over 12 month

48 hours

months

12 months
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SITE
S1 Vaginal; area

S2 Vaginal;

S3

S4

S5

of suture line

away from area

Trocar

Other skin or

Intra-

of suture line

passage

musculoskeletal

abdominal

Except S5

site

Table 1.7 Examples of Complications Related to Mesh-based Surgery in Female
Using the International Urogynecological Association (IUGA)/ International
Continence Society (ICS) Joint Classification System
Patient ID

Clinical Description of

Code

Code

Complication
100

Retropubic hematoma following a

7A/T1/S3

tape procedure (first 24 hours)
101

Persistent thigh pain six weeks after

6B/T2/S4

an obturator tape
102

Bowel obstruction and 2 cm vaginal

5C/T3/S5

3B/T3/S1

vault exposure with bleeding six
months after a mesh sacrocolpopexy

1.3.2 Complications of Synthetic Slings Placed via
Transobturator Approach

The anatomic differences between the inside-out and outside-in approaches
of transobturator tape (TOT) insertion have been compared, especially in
terms of adverse outcomes. One method of studying such differences in
anatomy was through cadaveric dissection of the pelvis after performing
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sling surgery. When studying the inside-out technique of TOT insertion of
the sling, the sling was found outside the pelvic space and did not penetrate
the levator ani muscular group (2) (14). Risk of perforating bladder has been
identified in those studies (2). Such injury is usually easily identified
intraoperative if cystoscopy is carried out after passage of needle and tape.

Vaginal erosion and extrusion risk appears to be significantly related to
mechanical properties of the mesh utilized. An incidence of up to 15% of
vaginal extrusion and erosion had been reported with old meshes, and
obturator and ischiorectal abscesses, sinus formation, and voiding difficulty
were all noted (2). Newer polypropylene slings have lower incidence of
erosion and extrusion.

Infectious complications also have been reported with TOT, such as
abscesses, adductor myositis, and cellulitis (2). Cases of infected obturator
hematoma requiring exploration and drainage have been also reported. As
with vaginal erosion, risk of infectious complications decreased with the
new slings. Urinary tract infection (UTI) has been reported to occur post
TOT procedure in a rate between 7.4% and 13% (14), and it was under
reported as postoperative complications, perhaps due to an improper
definition and under reporting of UTI as a complication (14). It is usually
managed with antibiotics with the same guidance and rules that govern the
use of antibiotic for UTIsin other clinical scenarios.

Postoperative voiding dysfunction has an incidence between 2.1% and 6.7%
after TOT techniques (2). Urinary obstructive symptoms rate varies between
1.5% and 15.6% of cases (2). They are usually temporary and managed with
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short-term intermittent catheterization. Rarely, obstruction lasts longer than
expected, and patients improve when the sling is incised or removed with a
second operation (2).

Postoperative leg pain is a unique complication to TOT procedures, reported
in up to 15.9% of patients (2) (14). It’s usually transient, responds to nonsteroidal anti-inflammatory medications, and improves shortly after surgery.
It’s likely due to subclinical hematoma or a transient neuropathic
phenomenon (2). Pain can be felt down the leg or in the groin area. Cases
that do not respond to conservative therapy should prompt investigation to
role out tape erosion. Therapy with corticosteroids and local anesthetic
agents might be required in some cases (2). Sling resection or urethrolysis
sometime is needed.

1.3.3 Complications of Synthetic Slings Placed via Retropubic
Approaches

Vaginal erosion or exposure of sling into vagina is a complication following
TVT procedure, similar to TOT slings (2). It’s manifested clinically by
vaginal discharge, sexual discomfort or dyspareunia, non-specific lower
urinary tract symptoms, and pelvic pain. However, up to one third of patients
with vaginal erosion may be asymptomatic (14). Cases usually present
within the first few weeks to few months of the procedure, and continence is
usually maintained. Factors such as biomechanical properties of the mesh
used, tissue healing and infection, thin, atrophic vaginal wall (as in post-
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menopausal status), and incorrect surgical technique all were addressed as
influencing factors to vaginal erosion (14). Cases are managed on individual
basis, and conservative management, surgical removal of the exposed mesh,
and even more aggressive surgical intervention has been reported to be
effective in managing mesh erosion or exposure (2) (14).

Urethral erosion is a complication that can be associated with severe
morbidity (14) (15). It’s rare after retropubic approaches of sling placement
surgery, with an incidence of less than 0.3% (2) (14). Possible risk factors
include compromised blood supply to the urethra (such as post radiation
cases), excessive sling tension or twisting of the tape, and iatrogenic urethral
injury intraoperative. Also, surgical technique may increase the risk of
urethral erosion, as carrying out dissection too close to the urethra can cause
urethral devascularization (2). Patients with urethral erosion present in most
instances with voiding dysfunction symptoms like urgency and urge
incontinence, urinary obstruction and/ or retention, and recurrent UTI. Also,
persistent urinary incontinence is a potential symptom of erosion of the tape
into the urethra (2). Intraoperative cystoscopy is highly recommended to
identify iatrogenic injury to the urethra. It makes a significant difference in
the patient outcome if an injury is addressed at the time of the procedure.
There is no role for conservative management for urethral erosion, and cases
that present later have to be treated with an endoscopic procedure or
transvaginal urethrotomy and excision of the exposed tape (2). In cases with
more urethral lumen or surface compromise, graft may have to be
considered for repair.
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Bladder perforation while passing the needle to place the sling in the vaginal
wound has been reported with retropubic approach. Rates range between
0.7% and 24%, and it’s mostly related to surgeon experience, as incidence
was noted to decrease when experience with the procedure increased (14).
As with urethral injury, bladder perforation can be identified and corrected
intraoperatively if cystoscopy is performed. The trocar is repositioned and
the sling is placed in the appropriate place, and an indwelling catheter is left
for a few days post operative (2). If it’s not addressed intraoperative, the
patients may presents with irritative bladder symptoms such as urgency and
frequency. Some cases may present with fistulas with need for more
aggressive intervention (14).

Intravesical tape erosion may be a distressing later symptom of bladder
perforation if it was missed intraoperative. It is less common to have true
erosion through the seromuscular layer of bladder (2). Typical symptoms
might be lower abdominal pain, intermittent gross hematuria, recurrent UTI,
frequency, urgency, and urinary incontinence. As with urethral erosion, ther
is no role for conservative management in cases with intravesical sling
erosion, and removal of a portion of tape with reconstruction of the urinary
tract is the standard therapeutic approach (2). Patients usually maintain their
continence if only the intravesical portion of the sling is removed.

Voiding dysfunction is a well-documented complication after all sling
surgeries (2) (16). It usually presents as varying degrees of urinary
obstruction (2) (13) (14). Reported incidence varies in different studies with
rate between 1.9% and 19.7% (2) (14), and it seems that rate increases with
prolonged follow up period (13). UDS has been used in multiple studies to
22

address parameters like urine flow, filling time, voiding time, and maximum
voiding pressure, and compare those parameters before and after sling
surgeries, thus, anticipate cases with possible post sling surgery voiding
dysfunction. However, no enough evidences correlate UDS parameters with
surgical outcome (2). Yet, it’s vital to identify factors that might negatively
affect outcome and predispose to post operative urinary retention, like age,
parity, and peak flow rate on UDS (16). Also, it was found that patients who
have lower detrusor voiding pressure are more likely to have urinary
retention postoperatively (16). Another factor that may increase the risk of
voiding dysfunction after sling surgery is concomitant prolapse surgery (16).
Finally, local tissue criteria like abnormal positioning of the sling at bladder
neck level, scarring of the bladder neck, and presence of paravaginal defects
have been noted in patients with urinary obstruction (13). Hypothesized
mechanisms for urethral obstruction after sling surgery included
hyperelevation of bladder neck and/ or an exaggerated kink in the urethra
(16). Clinical picture includes different presentations; patient may complain
of difficulty in initiation urine stream, straining while voiding, incomplete
emptying or total urinary retention (2). A thorough history and physical
examination are vital in the initial evaluation and before any surgical
intervention is carried out. Cystoscopy helps in the diagnosis mainly through
exclusion of other causes of urinary obstruction. First line of management
includes temporarily indwelling catheter use, intermittent catheterization, or
timed and double voiding (2) (14). If symptoms persist, surgical intervention
is advised. It’s recommended to wait at least four weeks before surgical
intervention is considered (2) (13) (14). Release of sling with minimal
vaginal dissection is usually sufficient with maintained continence through
the support of urethra from the remaining portions of the sling (2).
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Other complications of sling surgery have been reported in minor
percentages. Wound–related complications like infection, abscesses and UTI
have been addressed. Serious complications like vascular injury and
hemorrhage into pelvis have been also reported, and at least one case leading
to mortality (2) (14). Postoperative dyspareunia has been reported in up to
15% of patients who underwent sling surgery (2) (14). It was attributed to
the physical properties of the sling that cause shrinkage and/ or migration.

Review of the safety database of U.S Food and Drug Administration for
complications reported to that agency is listed in Table 1.8.

Table 1.8 Summary of All significant Complications Reported to the U.S Food and
Drug Administration with Midurethral Sling (1998-2009)

Complication

No. Of cases reported

Bladder erosion

50

Urethral erosion

51

Vaginal erosion

239

Bowel perforation

48

Major vascular

26

Blood loss > 200ml

36

Plastic sheath malfunction

51

Leg pain

44

Needle broken from mesh

154
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2

Literature Review

Complications of synthetic sling surgery can be related to patient’s
factors, provider’ factors, surgical techniques, and the physical properties of
sling itself. In the literature, complications were mainly described in relation
to their time of diagnosis in postoperative follow up, or in relation to
surgical approaches commenced in the surgery. As described previously, a
recent classification system was standardized by IUGA and the ICS joint
committee to describe and diagnose complications related to meshes, tapes,
or implants surgery in female, however, it is not yet widely used in
evaluation of those complications either in clinical practice or in literature.

2.1 Food and Drug Administration (FDA) Warning about the
Use of Surgical Mesh for SUI

After the approval of synthetic sling use in United States (USA) in 1998 by
the Food and Drug Administration (FDA), urologists and gynecologists all
over the world started performing mid-urethral sling surgeries. In 2011, over
3 million mid-urethral slings had been sold worldwide (17). The procedure
is considered safe, however, in October 2008, FDA issued a public health
notification (and updated it on July 2011) about slings and meshes used in
gynecological surgery (18) (19). The notification was issued after the agency
received more than 1,000 reports of complications associated with the use of
meshes for both pelvic organs prolapse (POP) repair and SUI correction.
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Vaginal erosion, pain, infection, and recurrence of prolapse and/or
incontinence were among those rare complications (18). FDA did not advise
cessation of surgical meshes usage; it did recommend “specialized training
for mesh placement technique” and thorough counseling with patients about
properties of mesh, and “that complications associated with the implanted
mesh may require additional surgery that may or may not correct the
complications” (18). The updated statement issued in 2011 had a significant
distinction: “serious complications associated with surgical mesh for
transvaginal repair of POP are not rare”, and it was plainly stated that POP
repair with mesh is “not clearly more effective than traditional non-mesh
repair”. Indeed, mesh may expose patients to “greater risk” compared to
traditional surgical approach (19). This severed to separate mesh used for
POP compare to mesh used for SUI surgeries. However, the FDA did not
declare special concern related to SUI surgeries using synthetic mesh, and
most complications were related to POP surgeries using mesh. That being
said, the FDA in 2013 stated explicitly “that safety and effectiveness of
multi-incision slings is well established in clinical trials that followed
patients for up to one-year” (20), and there were no recommendations or
advice to chose non mesh-based intervention for SUI. None of the FDA
communications or notifications regarding mesh use in pelvic reconstructive
surgery in general was related to a recall (17).

It was necessary to discus the warnings and concerns of the FDA regarding
surgical use of mesh in pelvic surgery due to the confusion that occurred in
both parties involved in this issue: health practitioners and patients,
especially with the appearance of different reports and investigations in
media and the commencement of multiple lawsuits in U.S and Canada.
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2.2 Complications Rates in Literature

A literature search for the incidence of complications associated with
synthetic sling use in SUI can be quit difficult. Investigators tend to report
complications of synthetic slings that were placed during POP repair
procedure, which can makes such results confusing. Another challenging
issue is the ambiguous terminology of different complications used in
different studies and reviews. For example, voiding dysfunction can be
defined as the inability to void completely, inability to empty the bladder
comfortably, or dysuria, which is confusing, and many articles do not
specify the definition they use. Likewise, pain may be reported post
operatively as complication; most articles didn’t use a pain scale either
initially or in follow up.

Characteristics of patients reviewed are another limitation when assessing
incidence rate of sling-related complications, as most of the patients were
not homogenous in their surgical history, and several studies did not
differentiate between patients who underwent sling surgery as primary antiincontinent surgery and those who had recurrent SUI treated with previous
sling or non-sling procedure. All those factors may contaminate the true rate
of complications of synthetic sling surgery as a variable, and influence the
analysis of true factors likely causing those complications.

One last issue about the true incidence of complications is the actuality of
reported complications in literatures. Many centers and health practitioners
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in the world do not publish articles or studies about synthetic sling
complications for different reasons; they would just report them to the local
authorities according to established protocols in their administrative setting.
This may present literature with an inaccurate complications rate, which was
demonstrated in one study that compared complications rate reported in
literature between 2001 and 2005 with the rate found in FDA’s
Manufacturer and User Device Experience (MAUDE) database (21). There
was significant discrepancy between the two rates with the one reported in
MAUDE higher than those published in literature. The authors explained
this difference with the fact that some complications related to urethral and
bladder perforation can present with mild urinary symptoms, which make
them less likely to be reported (21).

2.3 Perioperative and Immediate Postoperative Complications

As mentioned previously, synthetic sling- related complications could be
categorized in relation to their clinical presentation timing to perioperative
or immediate postoperative complications, and late postoperative
complications. We’ll discus here incidence rate of perioperative and
immediate postoperative complications.

2.3.1 Bladder Perforation

A meta-analysis of randomized controlled trials that compared tension-free
midurethral tapes to other surgical procedures carried out by Novara et al in
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2008 showed that retropubic approaches was more likely to cause bladder
perforation (22). This was evident in other studies (14) (23), and several
systematic reviews (24) (25) (26). Novara et al did update their systematic
review two years later and found the same result regarding bladder
perforation risk (27). Stanford et al found in their review of all urethral
slings complications that overall incidence of abdominal and pelvic organ
injury including bladder was 3.3% (28), however, intraoperative bladder
perforation rates of up to 24% have been reported (29).
Incidence of bladder perforation/injury in retropubic approaches in general is
low, as reported by Kuuva et al in their nationwide analysis of TVT sling
procedure and Abouassaly et al in a multi-institutional review as 3.8% and
5.8%, respectively (30) (31).

2.3.2 Urethral Injury
The urethra is also at risk of injury during SUI corrective surgery using a
synthetic sling. One review of urethral injury rate showed no statistically
significant difference in its incidence between retropubic and transobturator
approaches (29). However, a meta-analysis done by Schimpf et al. showed
that urethral injury cases were fewer in the transobturator approach (25).
Authors in the former review reported a median incidence rate of urethral
injury at both retropubic and transobturator approaches to be 0.88% (range
0.1-5.5%) and 1.09% (range 0.0-2.5%), respectively. They identified risk
factors like previous pelvic surgery, infection, radiotherapy, and experience
of the surgeon. Along with their literature review, authors also reported 14
cases of urethral injury identified in their center, and they concluded based
on their criteria and findings that fistula, diverticulum formation and
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symptomatic outflow obstruction are serious squeals to urethral injury, and
recurrent or persistent stress urinary incontinence is common, for which they
recommended cystourethroscopy as part of all mid-urethral sling procedures.

2.3.3 Major Vascular Injury
Major vascular injury during synthetic sling surgery can be serious, although
rare in occurrence. Vascular injuries involving large arteries like the external
iliac, femoral, obturator, epigastric and inferior vesical have been reported
(14). A review of the FDA MAUDE database between 2001 and 2005
revealed 36 cases of major vascular injury including three deaths (21).
Incidences between 0- 0.1% have been reported in four national registries of
synthetic slings procedures (32). Kuuva et al in their evaluation of 1455
cases reported an incidence of 0.07% for major vascular injury (30).

In a study to avoid vascular injury, Muir et al reviewed and described the
vascular anatomy of lower pelvis in relation to insertion of tension-free
vaginal tape (33). They used fresh frozen cadavers in their study, and they
performed tension-free tape insertion in three different planes in relation to
needle passage, then they evaluated distance to different vessels. The mean
distance from the tape needle to the obturator vessels was the closest: 3.2 cm
(range 1.6–4.3 cm). The mean distance from the tape needle to the
superficial epigastric vessels was 3.9 cm (range 0.9–6.7); to the inferior
epigastric vessels, 3.9 cm (range 1.9–6.6 cm); and to the external iliac
vessels, 4.9 cm (range 2.9–6.2 cm). When the needle was directed 6 cm
lateral to the mid–biceps brachii muscle (according to planes already
constructed), the external iliac vein was punctured.
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2.3.4 Voiding Dysfunction
Voiding dysfunction is a common complication after synthetic sling surgery,
and symptoms can be related to storage phase or voiding phase. Reviewing
the literature for voiding difficulty is challenging because of its inconsistent
definition among different studies. Some studies and reviews differentiate
between incomplete emptying (as manifested by post void residual more
than 100 ml) and complete retention. Other studies don’t do that and only
report, “voiding dysfunction” without clear definition. This makes
evaluation of its true incidence a very difficult target. Added to this, the
heterogeneity of patients reviewed in their past surgical history makes it
doubtful to attribute postoperative voiding difficulty to the sling procedure
solely.

The incidence of voiding lower urinary tract symptoms (LUTS) varies
between 3.3% up to 54.9% in randomized controlled trials assessing
different surgical kits in the retropubic approach (22). In an analysis of 404
cases of SUI who underwent tension-free vaginal tape procedure in
prospective multicenter study, voiding difficulty was noticed in 4% of
patients (34). Abouassaly et al noticed in their multi-institutional review that
19.7% of patients who underwent tension-free tape had a urinary retention
for more than 24 hours postoperative (31), almost two-thirds of them were in
retention for less than 48 hours, and the other one-third were treated with an
indwelling catheter or clean intermittent catheterization for a mean period of
22 days. In seven patients the tape was released to treat the retention, and it
was sectioned in three. Kuuva et al reported low incidence rates of both
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minor voiding difficulty and complete urinary retention as 7.6% and 2.3%,
respectively with retropubic approaches of sling placement (30). Difficulty
in emptying and/or retention were the main presenting symptoms in 9 out of
21 cases of retropubic sling procedure at a tertiary referral center (21). Cases
varied in their presentation time; 6 cases presented immediately
postoperatively, and the other 3 presented in less than two weeks.

Several comparison studies and meta-analysis found no statistical/clinical
significance in immediate postoperative voiding difficulty between
retropubic and transobturator approaches of synthetic sling placement (24)
(25) (27) (35) (36). Reported rates of postoperative obstruction after
synthetic slings surgery in general range from 1.9% to 19.7% (14). In one
review by Petri et al, however, obstruction was noted in 48% of patients
presented with complications (13). Interestingly, analysis of 233 cases
underwent TOT sling procedure with 27 months follow-up found no
difference in term of urinary retention earlier in postoperative period
between women who had sling surgery compared to women who had sling
surgery and another surgical procedure (37).

2.3.5 Other Complications
Other immediate postoperative complications like UTI, groin pain,
hematoma and wound related complications were also reported in the
literature. Table 2.1 summarizes some of those complications reported in
selected articles.
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Table 2.1 Non-frequent Reported Complications Related to Synthetic Slings in
Different Studies
Reference

No. Of

Follow-

Hematoma Groin/

Wound

UTI

Case

up

(%)

related

(%)

Thigh

(Months)
Kaelin-

233

Gambirasio

(TOT)

pain (%)

27

0.4

NR

NR

NR

> 120

2

2.5

1.6

10

NR

1.9

NR

0.4

12

35

1.5

NR

0.5

NR

4-24

NR

NR

NR

0

48

1.7

NR

0.9

10.9

et al (37)
Petri et al

359

(13)

(Suburet
hral
Slings)

Abouassaly

241

et al (31)

(TVT)

Meschia et

404

al (34)

(TVT)

Neuman M

300

(38)

(TVTO)

Karram M

350

(39)

(TVT)

33

2.4 Late Postoperative Complications

Long-term follow-up of patients who underwent synthetic sling surgery for
SUI may help to detect late postoperative complications as soon as they are
evident, so proper medical intervention can be initiated immediately. Two
complications commonly reported in long-term follow-up after synthetic
sling surgeries are discussed here.

2.4.1 De novo Urgency and Urge Incontinence
De novo urgency was among the commonest long-term complications
reported after synthetic sling surgery for SUI. It was noted with other
irritative LUTS after synthetic sling surgery. It’s incidence varied between 0
to 25.9% in different studies(14). Recent meta-analysis showed that
postoperative overactive bladder (OAB) symptoms were more common in
patients who had retropubic slings (25). Novara et al reported similar
findings in their updated systematic review, although when they did metaanalysis of high-quality RCTs no statistical significance was noted (27).
Urgency and/or urge incontinence can be an early sign of mesh
misplacement, whether in urethra, bladder neck, or bladder itself. Deng et al
in their review of complicated cases post synthetic slings procedures found
mesh in the urethra and/or bladder in ten cases presented with irritative
LUTS (21). Holmgren et al did another review that included 463 women
who had TVT for genuine SUI for de novo urgency incidence and found it to
be 14.5% (40). Based on their analysis of all women criteria, they found that
older age, parity, and history of cesarean section were significant risk
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factors. Petri in his review of 359 cases of synthetic sling surgery
complications concluded that de novo OAB seems to be the commonest
complication with rate of 54% (13). He did recommend changes in the new
IUGA-ICS classifications of complications to adapt this complication.

2.4.2 Vaginal Erosion
Vaginal erosion is defined as “the presence of foreign material (sutures,
sling material) within the vagina after vaginal wound healing” (41). It used
to be reported more commonly, which could be attributed to the types of
meshes used initially and their mechanical properties. Also, types of surgical
devices that were available in the market previously contributed to higher
rates of erosion, for which they were recalled because of their overall higher
risk of complications (14) (27) (37). Lack of cumulative experience with
both proper wound dissection and proper placement of tape are other
influencing factors.

A prospective study by Chen et al analyzed the possible risk factors for
vaginal tape erosion after synthetic sling surgery in 233 women who
underwent sling surgery for SUI (41). They reported erosion in 6 patients,
and among clinical risk factors they assessed for erosion only diabetes
mellitus (DM) was a significant one. Thus, they advised counseling women
with DM that vaginal erosion is a possible complication after tape
procedure. Another analysis of 233 women who underwent TOT procedure
found that age, body mass index (BMI), and concomitant pelvic procedure
were not statistically significant risk factors for erosion (37). Petri et al in
their review of 359 cases with synthetic sling related complications reported
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vaginal exposure in 68 patients (13), and it was among the commonest three
complications in that group.

Two meta-analysis reviews compared the retropubic to the transobturator
approach in vaginal erosion risk, and found increased risk with the
transobturator approach (24) (25). On the other hand, another meta-analysis
done in 2008 and updated in 2010 found no statistically significant
difference between the two approaches (22) (27). Tommaselli et al did a
recent meta-analysis, and found that transobturator approach in synthetic
sling surgery was associated with increase risk of both vaginal injury and
erosion (26). This discrepancy could be explained by the criteria of the
RCTs included in those meta-analyses. Another possible reason is the
inclusion of studies reported on use of older surgical device for
transobturator insertion of synthetic sling, which was known to be associated
with a higher incidence of erosion.
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3

Methodology

The purpose of our study was to: 1) estimate the incidence of synthetic sling
removal after synthetic sling surgery for SUI, 2) assess the possible impact
of surgical volume and specialty of the provider surgeon on this incidence,
and, 3) to evaluate other risk factors for sling removal.

3.1 Study Design

We conducted a retrospective population-based cohort study examining all
adult women who underwent a SUI synthetic sling procedure in the period
between April 2002 and December 2012 (fiscal year 2002/03 to 2011/12).
Our study was conducted in Ontario, Canada, a province of over 13 million
residents (42) with nearly universal health care access, and coverage of
government funded health care system. No patient consent was required as
our data were administrative in nature. The research ethics board at
Sunnybrook Hospital, Toronto, Canada, approved the study.

3.2 Data Source
Data regarding the cohort, outcome, and different variables measured were
collected using linked health care databases via Institute for Clinical
Evaluative Sciences (ICES), which is a not-for-profit research institute made
up of a community of research, data and clinical experts, and a secure and
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accessible set of Ontario's health-related data such as population- based
health surveys, as well as clinical and administrative database (43).

Canadian Institute for Health Information (CIHI) was one source of data in
our study. It manages a number of databases as part of its contribution to the
health care system in Canada. Discharge Abstract Database (DAD) and
Same Day Surgery (SDS) are two of those databases, and were used to
identify our cohort with their primary and secondary diagnosis, day- surgery
procedures, discharges, and death records.

The Ontario Health Insurance Plan (OHIP) database was also used in our
study. The ministry of health maintains it and it has records for all
physicians’ payments to Ontario doctors. It also includes all claims
submitted whether services were on an inpatient or out patient basis.

Data quality measures have been carried out to ensure a high-quality
administrative data in all three data sources. One measure was through
conducting a review of published and unpublished studies in Canada to
assess the completeness of data and the level of agreement across different
databases (44) (45). Quality of data was assessed through three criteria:
Completeness of the data, agreement of information when data from one
database was compared to the same information obtained from another
database, and agreement of diagnosis with experts’ opinion. After this
review that was done in 2000, it was concluded that demographic
information on patient age, sex and residence was complete and reliable, and
there were a high levels of agreement on specific surgical procedure codes
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found in hospital discharge data and medical claims (45). Also, billing
claims for physician services provided complete capture of procedure codes.

3.3 Patients Population

All adult women above the age of 18 years who underwent SUI synthetic
sling procedure in Ontario in the period of April 2002 to December 2012
were identified and included in our study. Canadian Classification of Health
Intervention (CCI) codes from the CIHI-DAD/SDS database were used to
identify the patients (Appendix B). CCI code system is the standard coding
system used for classification of health-related interventions in Canada, and
it is the companion classification system to International Classification of
Disease (ICD) in its 10th revision (46).

The CCI coding system was revised more than once through adding new
codes and updating existing ones to accommodate new procedures and
surgical approaches. These changes were considered in identifying cohort
patients in our study. Also, as different surgical kits had different entry times
to the markets, possible CCI codes for all different kits were assessed,
revised and included during data collection.

We set a look back window of five years prior to index date to prevent
contamination of our primary outcome and to ensure completeness and
validity of the data. Certain exclusion criteria (Table 3.1) were applied to
cohort patients using OHIP and CCI codes for the same above reasons. Prior
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pelvic surgical interventions using meshes like anti incontinence surgery or
POP repair can influence the result of index synthetic sling surgery, thus
affect its complications whether in nature of complication or its prevalence.
So, such cases were excluded. However, patients who underwent
simultaneous or subsequent non-mesh based POP surgery were included in
the study to monitor the effect of concomitant pelvic surgery on SUI
surgery.

Table 3.1 Exclusion Criteria in Cohort Patients
Exclusion Criteria
Prior incontinence surgery
Prior vaginal prolapse repair surgery
Additional SUI/POP surgery performed within 1 week of index event
Neurogenic diagnosis

As patients were identified through linked administrative databases,
additional exclusion criteria were applied for data cleaning to ensure the
highest quality of data. For examples, patients with missing or invalid health
record number, missing or male sex, and missing birth date were excluded.
In addition, patients who were not permanent residents in Ontario were
excluded to ensure best longitudinal follow up for cohort.
All these exclusion criteria were assessed and applied using CCI/CCP and
OHIP codes as mentioned previously. Such codes could be traced back to
1992, when a well-established electronic coding system using CCI was
available and traceable.

40

Index date was assigned as the date of SUI surgery using synthetic mesh,
and observation of cohort was continued until death, first occurrence of an
outcome, date of last contact of patient with health care system as follow up
plus one year, or the end of the study, that was determined by March 31st
2013.

3.4 Primary Outcome

The primary outcome was defined as the first reoperation for SUI meshrelated complications. CCI codes were used in identifying outcome, and all
possible codes related to mesh complications surgeries were included. For
example, codes related to removal of foreign body in urethra, division,
extraction of foreign body in vagina, and urethrolysis were included. Also,
codes describing endoscopic treatment of foreign body or mesh encrustation
in bladder were assessed and included. In an attempt to include all
operations related to SUI mesh sling complications in the cohort, CCI codes
specific to management of bladder neck slings were included, like removal
of internal device (i.e. sling), taking into considerations different approaches
(like open, vagina, endoscopic). Different CCI codes used to define primary
outcome are outlined in Appendix C.

When two outcomes were found in one patient, the first recorded one was
marked as the primary outcome. Any CCI code with less than 6 in number of
patients (i.e. number of patients experienced outcome with that CCI code) its
actual value was not reported for privacy issues.
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3.5 Primary Exposures

Surgeon volume and surgeon specialty were identified as primary exposures
of interest in our study. Surgeon volume was defined as the number of
synthetic sling procedures for SUI done per year, which is assessed by the
hospital administration on a yearly basis. Surgeons are categorized in
databases as high-volume and low-volume providers. High-volume surgeons
are defined as being above or at the 75th percentile for sling surgery number
in a given year, and surgeons’ status could change from high to low-volume
category and vice versa; surgical volume was checked on a yearly basis.
This was considered and included in our study data, and it was tracked via
CIHI-DAD/SDS databases.
Surgeon specialty was determined as urologist, obstetrician/gynecologist, or
undetermined. It was also accessed via CIHI-DAD/SDS database.
Undetermined group of surgeons who did the synthetic sling surgery were
created after failure to specify their specialty through database.

3.6 Secondary Exposures

As our study was designed to be both a descriptive and analytic
observational cohort with a large number of patients, we also evaluated the
effect of other factors on the incidence of reoperation for SUI slingcomplications. The number of implanted slings to treat SUI was evaluated as
one of the secondary exposures. So, we identified all patients who had two
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or more synthetic mesh implant to treat SUI and we assessed their risk for
higher incidence of complication- related surgery.

Patients with known risk factors for synthetic sling complications were
evaluated as one group. Those factors are: previous urinary fistula, urethral
diverticulum, pelvic radiation and urethral injury. Diagnosis of these
conditions was identified by CCI codes in the cohort patients. They were
examined as a secondary exposure.

The setting of health facility that sling was implanted in was evaluated as
possible risk factor for sling complications occurrence. Hospitals were
categorized as academic and community hospitals, and patients’ initial sling
implant was grouped accordingly.

Other risk factors that might affect the incidence rate of reoperation after
SUI sling surgery included: age, concomitant pelvic surgeries at the time of
sling implant without mesh (like POP repair), obesity, and DM. They were
considered as secondary exposures and evaluated independently.

All those covariates were defined using different defining codes from both
databases of OHIP and CIHI-DAD/SDS (Appendix D). A summary of both
primary and secondary exposures evaluated in our study is obtained in Table
3.2.
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Table 3.2 Primary and Secondary Exposures
Primary Exposures
Surgeon Surgical Volume
Surgeon’ Specialty
Secondary Exposures
Age
Concomitant surgeries (Hysterectomy, POP repair)
DM
Obesity
High risk patients (H/O urethral diverticulum, urethral injury, urinary fistula, pelvic
radiation
Multiple synthetic sling implant for SUI
Academic hospitals

3.7. Statistical Analysis

As mentioned previously, one of our objectives was to evaluate specific
factors (as an independent variables) on the rate of reoperation for SUI
complications. An important variable was surgeon’ surgical volume, so, we
subcategorized patients into two groups and reported baseline characteristics
based on high and low volume surgeons. Baseline characteristics are
reported in Table 3.3. Those criteria were reported in either numbers with
corresponding percentage or medians with their corresponding interquartile
range (IQR). IQR was used as out measure of spread of our data points.

44

Table 3.3 Reported Baseline Characteristics of Patients
Characteristics of Cohort Patients
Age
Obesity (BMI > 40)
DM
Concomitant hysterectomy
Prior hysterectomy
Prior non-mesh-based surgery for POP
Concomitant non-mesh-based surgery for POP
> 1 Synthetic sling implant for SUI
High risk patients
Fiscal year of cohort entry (Index date)
Surgeon specialty (Urology, Obstetrics/gynecology/unknown)
Teaching hospitals
No. Of health care resources used 1 year before synthetic sling implant for SUI
Death after index date
Emigration

Comparability of the two groups of cohort patients on their baseline criteria
was carried out using standardized differences of the mean (SDM), which is
more informative than traditional hypothesis testing, especially in large
sample/group size of observational research as our study had (47). To
measure strength of any association between surgical volume and different
enlisted baseline criteria, a standardized difference of more than 10% (or
0.1) was considered significant (48).

We conducted a multivariable survival analysis as primary analysis for our
data, and we included surgeon’ volume, surgeon’ specialty, high-risk
patients, and the multiple mesh implanted group. Our study examined the
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cohort patients with different index dates over ten years (i.e. different entry
points) and different time period to complication surgery (primary outcome).
For which, hazard ratio (HR) with confidence interval (CI) was calculated to
estimate the risk of primary outcome over the study time period. CI of 95%
was reported for clinical significance.

Multivariable analysis was run using the PROC PHREG procedure in SAS
software (version9.3; SAS Institute Inc.), and a Cox proportional hazards
regression model was used to assess the effect of different covariates on the
outcome over time. We adjusted for age, obesity, diabetes, concomitant
hysterectomy, prior hysterectomy and/or non-mesh-based surgery for POP,
concomitant non-mesh-based surgery for POP and hospital type. Cumulative
incidence rate of outcome was calculated using Kaplan- Meier survival
analyses, and Cochrane –Armitage test was used to assess the linear trend of
outcome and significant changes in the 1-year event rate over time.

4 RESULTS
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4.1 Baseline Characteristics

We identified 61,876 women who underwent synthetic sling implant for SUI
(Figure 4.1). 1,989 patients were excluded according to our predefined
exclusion criteria listed in table 4.1. A final cohort of 59,887 patients was
reviewed and analyzed, out of whom 1,740 patients died and 915 patients
were lost to follow up (identified by date of last contact with health care
system plus 1 year). We reached the end of the study with 55,925 patients.
The number of patients enrolled per fiscal year is outlined in figure 4.2 (as
our study endpoint was predetermined to be December 31st 2012, and fiscal
year starts on April 1st and ends on March 31st, the rest of data for 2012 were
extrapolated from the period January 2013-March 2013 based on available
data of the first 9 months), and a steady increase in patients’ number is
observed, likely due to the increase in popularity of synthetic slings as
minimally invasive procedure to treat SUI. Another possible reason is the
practice of “prophylactic MUS surgery” when performing POP repair.

Median age of patients was 52 years (IQR, 45-63), and median follow-up
was 4.4 years (IQR, 2.3-6.8). Surgical procedures were done by total of
1,068 surgeons, out of whom 625 were gynecologists (58.5%), 293 were
urologists (27.4%), and 150 (14%) were undetermined. Patients were
categorized according to surgical volume of their operating surgeon into two
groups (Table 4.2). High-volume surgeons were defined by being at the 75th
percentile or above for procedures performed for SUI yearly. They operated
on 44,140 (73.7%) patients (Figure 4.3).
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Table 4.1 Cohort Patients’ Exclusion Criteria
No. Of patients

Exclusion Criteria
Age < 18 years or > 100 years

9

Male/Missing gender

507

Non Ontario residence

37

Use of vaginal mesh for prolapse prior to 1st of April 2002

594

Use of vaginal mesh for prolapse after 1st of April 2002

507

Prior use of mesh for SUI

56

Missing hospital institution

279
Total = 1989

61,876 Patients
All slings cases

1,989
Patients
Excluded
59,887 Patients
1,740 Patients
Death

Reviewed
915 Patients

DOLC+1year

55,925 Patients
1,307 Patients
Primary
Outcome
Figure 4.1 Flow Chart of Cohort Patients
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Reached
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No. of patients with mesh based SUI
surgery
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Fiscal Year
Figure 4.2 Number of Patients Who had Mesh-based SUI Surgery Per Year between
2002- 2012. Note that number of patients in 2012 was derived from combined data
from both fiscal years 2012 and 2013 (see text)

15,747

44,140

Patients operated by
High surgical volume
providor
Patients operated by low
surgical volume
providors

Figure 4.3 Cohort Patient’s Distribution According to their providers’ surgical
volume.
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Table 4.2 Baseline Criteria of Patients in Relation to Surgeon’ Volume
High -Volume

Low-Volume

Standardized

Surgeons a

Surgeon

Difference of

(n=44140)

(n=15747)

the Meanb

Age, median (IQR), years

53 (45-63)

52 (45-63)

0.02

BMI >40, number (mean)

1976 (4.5)

698 (4.4)

0

Diabetes mellitus, number (mean)

5222 (11.8)

2036 (12.9)

0.03

Concomitant Hysterectomy,

5061 (11.5)

2603 (16.5)

0.14

3633 (8.2)

1329 (8.4)

0.01

13115 (29.7)

4743 (30.1)

0.01

2386 (5.4)

805 (5.1)

0.01

900 (2.0)

352 (2.2)

0.01

54 (0.1)

19 (0.1)

0

number (mean)
Prior Hysterectomy, number (mean)
Concomitant non-mesh-based
surgery for POP, number (mean)
Prior non-mesh-based surgery for
POP, number (mean)
> 1 Synthetic sling implant for SUI,
number (mean)
High risk patients c, number (mean)

Fiscal year of cohort entry (index date), number (mean)
2002

1917 (4.3)

668 (4.2)

0

2003

2664 (6.0)

859 (5.5)

0.02

2004

3199 (7.2)

1005 (6.4)

0.03

2005

4056 (9.2)

1251 (7.9)

0.05

2006

4144 (9.4)

1584 (10.1)

0.02

2007

4727 (10.7)

1669 (10.6)

0

2008

5218 (11.8)

1759 (11.2)

0.02

2009

5177 (11.7)

2055 (13.1)

0.04

2010

4836 (11.0)

1859 (11.8)

0.03

2011

4969 (11.3)

1835 (11.7)

0.01

2012

3233 (7.3)

1203 (7.6)

0.01
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High -Volume

Low-Volume

Standardized

Surgeons a

Surgeon

Difference of

(n=44140)

(n=15747)

the Meanb

Surgeon specialty
Urology number (mean)

18946 (42.9)

6648 (42.2)

0.01

Obstetrics/gynecology

25133 (56.9)

8837 (56.1)

0.02

61 (0.1)

262 (1.7)

0.17

12762 (28.9)

2562 (16.3)

0.30

Unknown number (mean)
Teaching/academic hospital

No. Of health care resources used 1 year before synthetic sling implant for SUI
number (IQR)
Family Physician visits,

6 (3-9)

6 (3-9)

0.05

Urology or Gynecology

2 (1-3)

3 (2-4)

0.26

Hospital admissions

0 (0-0)

0 (0-0)

0.04

Death after index event

1289 (2.9)

485 (3.1)

0.01

Emigration

683 (1.5)

232 (1.5)

0

Visits number (IQR)

Abbreviations: IQR, interquartile range; BMI, body mass index (calculated as weight in
kilograms divided by height in meters squared); POP, pelvic organ prolapse.
a
High volume surgeon is defined to be at or above the 75th percentile for mesh implants
for SUI in a given year.
b
A value of greater than 10% (0.1) is considered a meaningful difference between the two
groups.
c
Includes patients with fistula, urethral diverticulum, urethral injury, or post radiotherapy.

Significant differences between high and low-volume surgeons appear in
their clinical practice. High-volume surgeons (urologists or gynecologists)
saw patients less frequently before their SUI sling surgery (median, 2 [IQR,
1-3] vs. 3 [IQR, 2-4] visits; standardized difference, 0.26). They also were
less likely to do concomitant hysterectomy with SUI surgery (11.5% vs.
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16.5; standardized difference, 0.30), and they were more likely to do the
procedure in academic hospitals (28.9% vs. 16.3%; standardized difference,
0.30).

4.2 Primary Analysis

A total of 1307 women (2.2%) had the outcome, (removal or revision of
their mesh implant for SUI). Their distributions according to their provider’
surgical volume and specialty is illustrated in figures 3 and 4. The median of
time between original mesh-based procedure for SUI and removal date
among the 1307 patients was 0.94 (IQR, 0.35-2.49) years (Table 4.3).

417

890

Patients operated by
High surgical volume
providors
Patients operated by
Low surgical volume
providors

Figure 4.4 Description of Patients with Outcome in Relation to Their Provider’
Surgical Volume

52

11
584
712

Patients operated by
Urologists
Patiente operated by
OB/GYN
Patients operated by
Others

Figure 4.5 Description of Patients with Outcome in Relation to Their Provider’
Specialty

Table 4.3. Mesh Revision/ Removal After Mesh-Based Surgery for SUI
Entire Cohort
(n=59,887)
Duration of follow-up, median, (IQR), years

4.43 (2.35-6.88)

Total follow-up, person-years

282,801

Outcome, No. of patients, %

1307 (2.2)

Time from index date to outcome, median (IQR),

0.94 (0.35-2.49)

years
Event rate per 1000 patient-years of follow-up

4.62 (4.38-4.88)

(95% CI)

Calculation of cumulative incidence rate of outcome showed steady increase
over 10 years from 1.17 (95% CI, 1.09-1.27) at year 1 post index date to
3.29 (95% CI, 3.05-3.53) at 10 years post index date. Table 4.4 shows the
cumulative incidence rate by years of follow up.

53

Unadjusted analyses of patients who underwent revision or removal of mesh
showed that low-volume surgeons had a 37% (p < 0.0001) increase in
relative risk for mesh removal or revision in their patients compared to highvolume surgeons (Table 4.5). However, there was no significant difference
in rate of revision or removal of the mesh between gynecologists and
urologists (RR, 0.92; 95%CI, 0.82-1.02). Table 4.6 shows the unadjusted
analyses of patients who underwent mesh removal or revision in relation to
their provider’ specialty.

Table 4.4 The Cumulative Incidence Rate of Mesh Revision/ Removal After MeshBased SUI Surgery

Year

No. of patients
At the beginning
of follow-up
Censored

1

5 59,887

4563

Patients with
outcome
681

2

54,643

7042

234

1.63 (1.52-1.74)

3

47,367

6795

118

1.90 (1.78-2.020

4

40,454

7267

83

2.12 (2.00-2.46)

5

33,104

6955

64

2.33 (2.20-2.46)

6

26,085

6210

48

2.54 (2.39-2.69)

7

19,827

5504

28

2.69 (2.53-2.85)

8

14,295

5013

25

2.90 (2.72-3.08)

9

9257

3874

16

3.11 (2.91-3.31)

10

5367

3134

7

3.29 (3.05-3.53)
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Cumulative Incidence
(95%CI)
1.17 (1.09-1.27)

Table 4.5 Mesh Revision/ Removal After Mesh-Based Surgery for SUI Based on
Provider’ Surgical Volume
High-volume

Low-volume

Surgeons

Surgeon

(n=44,140)

(n=15,747)

Duration of follow-up, median, (IQR), years

4.5 (2.38-6.96)

4.24 (2.24-6.68)

Total follow-up, person-years

210,483

72,318

Outcome, No. of patients, %

890 (2.0)

417 (2.6)

Time from index date to outcome, median

0.94 (0.34-2.59)

0.93 (0.35-2.38)

4.23 (3.96-4.52)

5.77 (5.24-6.35)

1 (Reference)

1.37 (1.17-1.49)

(IQR), years
Event rate per 1000 patient-years of follow-up
(95% CI)
Unadjusted risk ratio (95% CI)

Multivariable analyses showed similar results regarding primary exposure
(Table 4.7). With Hazard ratio of 1.37 (95% CI, 1.21-1.55; P value <0.01),
patients who were operated on by low volume surgeon were more likely to
have a later surgery to remove or revise the mesh. No significant difference
was found between gynecologists and urologists in such risk (HR, 0.94;
95%CI, 0.83-1.08; P value, 0.38).
As we explained in our methodology, we adjusted for age, obesity, diabetes,
concomitant hysterectomy, prior hysterectomy and non-mesh-based surgery
for POP, concomitant non-mesh-based surgery for POP and hospital type.
Those factors were considered as potential confounders.
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Table 4.6 Mesh Revision/ Removal After Mesh-Based Surgery for SUI Based on
Surgeon’ Specialty
Urologists

Gynecologists

(n=25,594)

(n=33,970)

Duration of follow-up, median, (IQR), years

4.96 (2.68-7.46)

4.10 (2.13-6.38)

Total follow-up, person-years

131,036

150,074

Outcome, No. of patients, %

584 (2.3)

712 (2.1)

Time from index date to outcome, median

1.0 (0.32-2.82)

0.90 (0.37-2.23)

4.46 (4.11-4.83)

4.74 (4.41-5.11)

1 (Reference)

0.92 (0.82-1.02)

(IQR), years
Event rate per 1000 patient-years of followup (95% CI)
Unadjusted risk ratio (95% CI)

Table 4.7 Multivariable Survival Analysis to Assess Patients and Surgeon Risk
Factors For Removal or Revision of Synthetic Sling after SUI
Variable

HR (95 CI%)

P value

Surgeon Volume
High

1 (Reference)

Low

1.37 (1.21-1.55)

<0.01

Surgeon Specialty
Urology

1 (Reference)

Gynecology

0.94 (0.83-1.08)

0.38

4.73 (3.62-6.17)

<0.01

High risk patients a

0.58 (0.08-4.13)

0.59

Age per 10 years increase

0.86 (0.82-0.92)

<0.01

Obesity

0.82 (0.62-1.10)

0.19

Diabetes mellitus

1.11 (0.94-1.32)

0.22

Concomitant

1.24 (1.08-1.42)

<0.01

Multiple mesh-based
procedures for SUI
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Variable

HR (95 CI%)

P value

0.80 (0.66-0.97)

0.02

1.18 (1.02-1.36)

0.03

hysterectomy
Concomitant non-meshbased surgery for POP
Academic/ Teaching
hospital
Abbreviations: SUI, stress urinary incontinence; POP, pelvic organ prolapse.
a Includes patients with history of fistula, diverticulum, urethral injury, or radiotherapy

As per our secondary exposures, patients at higher risk for sling removal or
revision were grouped together and analyzed. We had a total of 73 patients
with the following high-risk features: history of urethral diverticulum or
injury, history of urinary fistula, and history of prior pelvic radiotherapy.
They did not show increase risk for sling removal or revision surgery (HR,
0.58; 95%CI, 0.08-4.13)

Concomitant hysterectomy at the time of sling implant for SUI did increase
patient’ risk for reoperation for sling revision or removal as outlined in table
4.7. However, non-mesh-based POP repair decreased the risk of reoperation
for a later complication, (HR, 0.80; 95%CI, 0.66-0.97).

A total of 1,252 patients had multiple synthetic slings implants for SUI, and
multivariable analysis showed significant increase in their risk for mesh
removal or revision (HR, 4.73; 95%CI, 3.62-6.17; p <0.01).
Finally, patients who had their SUI procedure in teaching hospital were
more likely to have their mesh removed or revised (HR, 1.18; 95%CI, 1.021.36; p= 0.03).
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5 DISCUSSION

SUI in women will remain a substantial problem with significant social and
economical impact. Surgical intervention based on the concept of
strengthening urethral tissue and pelvic floor muscles was tried as early as
1900s when Von Giordano used a muscle graft to support urethra (2).
Currently, as discussed in chapter one, synthetic sling or mesh-based
procedure has become the gold standard management for treating SUI in
female (1). However, this procedure is not without complications, for which
many studies were done and lot of reviews were carried out to outline and
predict those complications and estimate their incidence rate in different
setups. Our study was designed to measure the incidence rate of reoperation
for mesh-based complications and to study the effect of certain prespecified
factors, which were hypothesized to influence the risk of complications.

5.1 Principal Findings
In our large cohort study, we found that rate of removal or revision of
synthetic sling implanted for SUI was 2.2%, with a cumulative incidence
rate of 3.29% at 10 years of the initial procedure. As one of important
presumed predictors, surgeon’ specialty (urology or gynecology) was
evaluated, and our study showed that it has no effect on rate of reoperation
for complications. Another important factor we assessed was the surgical
volume of the operating surgeon, which did have an effect on the rate of
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mesh removal or revision, with low-volume surgeon having 37% higher risk
of reoperation on their patients. Other worthwhile findings about predictive
factors were as following; first, our study showed that implantation of more
than one synthetic sling increased the risk of complications by almost 5 folds
compared to single synthetic sling implantation. Second, we found that
concomitant hysterectomy did increase the risk of reoperation for meshrelated complications, however non-mesh-based POP surgery did not. Third,
patients who had their operation in an academic or teaching hospital were
more likely to have mesh-related complications. Finally, patients with
known risk factor for following complications after implantation of synthetic
sling, such as history of urethral injury or diverticulum, or had previous
pelvic radiotherapy did not express more risk for sling removal or revision.

5.2 Comparison with Previous Studies
Conducting literature review for incidence rate for sling revision or removal
after SUI surgery was challenging as most of authors reported incidence
rates that were specific to certain reasons only like voiding dysfunction
rather than the incidence rate in general (49). Others would only report cases
series of sling removal due to different causes (50). One population-based
cohort study did assess long-term incidence rate of sling revision for mesh
erosion and urinary retention (51), and incidence rate of sling revision in
their study was consistent with our reported one, with a cumulative risk of
3.7% at 9 years follow-up. Another case-control study carried out in US
examined all women who underwent midurethral sling placement for SUI
between January 2003 and December 2013 (52). Authors reported that 2.7%
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of their patients underwent sling revision for different reasons, which is also
close to incidence rate in our study.

As both urologists and gynecologists are involved in the management of SUI
in females, both specialties had carried out placement of mid-urethral slings
since synthetic sling appearance in late 1990s. Both specialties have
different training curriculum related to pelvic surgery due to the obvious
variation in daily practice. Studies had suggested differences between the
two specialties in the surgical management of SUI and outcome of synthetic
sling surgery (53), however, two studies showed no difference in incidence
of sling revision or urological and non-urological complications (54) (53).
Our study confirmed such finding, which emphasize the importance of
procedure-based training rather than surgical background and training. It
also supports the concept of similar basic surgical training programs or
courses for trainees from both specialties in the aspect of sling-based
surgery.

Volume-outcome relationship in health care has been evaluated and assessed
in several studies (55) (56) (57). Authors in those studies concluded that for
a numerous surgical procedures and medical conditions, higher volume
(whether assessed in relation to hospital or physicians) was linked to better
health outcomes. The strongest associations were found for acquired
immune disease syndrome (AIDS) treatment and for cancer-related
procedures like pancreatic cancer and esophageal cancer. Also the outcome
of abdominal aortic aneurysms surgery, and pediatric cardiac diseases
management was related to surgical volume (a median of 3.3 to 13 excess
deaths per 100 cases were attributed to low volume) (56). In urology,
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volume-outcome relationship have been also evaluated, mainly in urooncology procedures (58) (59) (60) (61) (62), with similar observation
regarding the inverse relationship between volume of surgeons or hospitals
and outcome measured by mortality rate, hospital stay, reoperation rate, or
complication rate. For mesh-based surgery for SUI, the role of surgeons’
surgical volume was not well assessed. One study assessed the surgeon’
volume effect on complications rate in pubovaginal sling procedures carried
out in US (63), where authors analyzed data from1356 patients underwent
sling procedures, and investigated differences between the two groups of
surgeons in surgical management of SUI in form of performing concomitant
POP at the time of sling procedure and in rate of repeat anti-incontinence
procedures and complications. They found that high-volume surgeons were
more likely to perform simultaneous POP at the time of sling surgery. They
also noticed that low-volume surgeons had higher reoperation rates to
correct prolapse during the first postoperative year. However, both groups
had no statistically significant difference in their rate of complications.

In our study, we did demonstrate a difference between high and low volume
surgeons with a 37% increase risk for reoperation for mesh-related
complications among low-volume surgeons. This supports the recent
recommendations from both specialized surgeons and surgical societies of
interest (64) (65), about the substantial need for adequate training in this
subspecialist area and the importance of a thorough understanding of the
relevant pelvic anatomy. Indeed, a review done by McLennan et al showed
that a learning curve does exist for tension-free vaginal tape procedures (66).
This was their conclusion after they evaluated 278 procedures done by 23
senior residents, and they assessed the rate of bladder perforation among
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patients. They found that incidence of perforation inversely related to the
number of cases performed. This shows the effect of increased number of
procedures performed (i.e. surgical volume) in the placement of SUI slings
and the complications rate (in more generalized view).

The assessment of different risk factors for mesh late complication after
placement of synthetic slings was reviewed widely in the literature in
relation to different surgical approaches and different surgical kits used. One
important factor was the placement of another synthetic sling to treat
recurrent SUI, and we did notice general acceptance of such practice in
different reviews and studies (67) (68) (69) (70). However, authors of those
studies did not investigate reoperation rate for late complication with longterm follow-up, which we think is an important influencing factor in
choosing appropriate management approach for recurrent SUI. In our study,
multiple synthetic slings (more than one) were placed in more 1300 patients,
and this increased their risk of undergoing another surgery for mesh-related
complications by almost 5-fold. We hope that enthusiastic surgeons will
consider our finding before they place a second or even third synthetic sling
when managing recurrent SUI. We won’t recommend stopping this practice
of placing multiple synthetic sling in patients who failed their primary
surgery; we do advise careful patients selection and thorough counseling
with them about potential risks, so patients are aware of all possible
complications and do participate in this decision. We also agree with the
recommendation to conduct multicenter, randomized clinical trials to look at
the management of recurrent SUI and the tools used to assess patients before
another surgical management (70).
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An interesting finding in our study was the inverse relationship between age
of patients and their risk for reoperation for mesh-related complication.
Increased age is not considered a contraindication for mid-urethral sling
placement for SUI; in fact a group of investigators from US analyzed data on
national level of women underwent SUI surgery from 1979 to 2004. They
found that the most significant increase in frequency of procedures was
among the population of patients age >52 years (71), which was attributed to
the fact of aging population and increase in number of women seeking care
for incontinence. Studies comparing outcome of mesh-based surgery for SUI
in elderly women compared to young women showed contradictory results
(72) (73) (74) (75) (76). However, no well-conducted review with an
appropriate long period follow-up assessed age as predictor factor for meshrelated complication surgery. In our study, median age among cohort
patients was 53 years, and risk for reoperation for complication was
significantly decreased with each 10 years increment. This can be explained
readily in the context of reasons for mesh revision or removal. Mesh erosion
is a common reason for mesh removal, and reports of conservative
management in literatures are sparse (2). Clinically, dyspareunia, vaginal
discharge, and lower urinary tract symptoms are prevalent symptoms, and as
older women tend to be less sexually active, this makes them less likely to
experience such symptoms; they may not seek aggressive surgical
management as a younger women might. Voiding difficulty or urinary
retention is another important cause for mesh revision. It’s usually managed
initially conservatively with temporary catheter drainage, clean intermittent
catheterization and timed voiding. However, if persistent, it needs revision.
Older women may be more tolerant of a degree of urinary obstruction
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compared to younger women, thus prompting more revisions in the younger
population for this reason.

Concomitant hysterectomy at the time of SUI sling surgery did increase risk
of reoperation due to mesh-related complication in our study. In the
literature, concomitant hysterectomy at the time of sling placement for SUI
was assessed as an influencing factor on the outcome of sling surgery, not on
later complications, and many studies had found no such influence(77) (78)
(79). However, the group from US who studied different predictors for sling
revision found that concomitant hysterectomy actually decreased risk of
sling revision (51). No other studies evaluated this variable. We think that
both results could be explained via surgical techniques and the nature of
tissues and their healing; however, as urologists do not perform concomitant
hysterectomy, we think that such predictors would not affect long term
results and complications of slings placement procedures performed by
urologists, and deserves more assessment.

An unanticipated finding in our study was the effect of facility in which
synthetic sling was implanted in on long-term risk for reoperation for
complication. Having sling implanted in an academic teaching hospital
raised the risk for a later removal or revision of that sling. The role of
teaching hospitals in training residents and medical students especially when
they are university-affiliated centers is paramount. Surgical residents and
students are involved with varying degrees in performing surgical
procedures and in the care of patients. This is the argument for hiring
clinicians with an academic background and competitive post-graduate
training in teaching hospitals. Moreover, in the last two decades, teaching
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hospital gained increased attention in national policy plan world-wide, and
several studies investigated the relationship between teaching centers and
quality of health care provided, measured by mortality rate, length of stay,
perioperative complications, and morbidity. For example, three studies done
in US evaluated mortality as a marker of quality of care, and it’s relationship
to teaching status of the facility serving patients in the field of
cardiovascular diseases (80) (81) (82), and all three studies showed lower
mortality rate in the cases treated in teaching hospitals. Other studies
assessed this relationship in major complex surgeries related to cancer, and
they had similar findings (83) (84). However, when it comes to more
confined surgeries like abdominal hysterectomy done for benign conditions
and rectal cancer surgery, studies showed no significant difference in
mortality between teachings versus non teaching hospitals (85) (86). In
mesh-based surgery for SUI, no studies were found evaluating this
relationship, apart from one done in Taiwan (87), where they assessed type
of facility (medical center, regional, and local hospitals) on reoperation rate
after SUI procedures, and they found no significant differences between all
three different hospitals. This finding was attributed by the investigators to
hospital’ volume rather than teaching status of it. In our study, such
difference in reoperation for mesh-related complications could be explained
by several factors. First, patients referred or treated in teaching hospital
usually are those with multiple comorbidities, which may increase their
original risk for complications. Second, as teaching hospitals usually cover
wider geographical region, their patient-volume would be bigger than those
of community non-teaching hospitals. Third, ongoing residency program in
teaching hospitals usually are more busy and packed with residents, who
may have higher morbidity rate in outcome of surgical procedures (88).
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Lastly, in our study patients considered to be at higher risk of reoperation for
mesh-related surgery did not in fact demonstrate a higher risk. Prior pelvic
radiotherapy, history of urethral injury or diverticulum, and prior urinary
fistula are all theoretical predisposing factors for later complications after
synthetic sling placement because they affect tissue healing and reaction to
foreign body, although this is based primarily on experts’ opinion. Our
results can be explained by the small number of patients with those
predisposed risk factors, which makes it even harder for future study and
better evaluation. Such results won’t change urologists or gynecologists’
daily practice of avoiding synthetic sling placement in this subset of patients,
but it may encourage them to apply the concept of sling placement in highly
selected patients when they have such presumed risk factors.

5.3 Strength and Limitations
Our study has evaluated a large number of patients who underwent SUI
surgery for the risk of reoperation for mesh-related complication. It has a
long follow-up period to document such complication-related operations.

We analyzed a data for almost 60,000 patients with synthetic sling implants,
with comprehensive data about their baseline criteria, their attending
surgeon’ specialty, and their attending surgeon’ experience measured as
surgical volume. This is a credit to the nature of administrative database in
Ontario, Canada, which was examined and assessed as we explained in
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methodology chapter. Moreover, due to the unique health care system in
Canada, and the accessibility of different people to one-government-based
medical facilities with different surgeons, from which we got our data, we
can generalize our findings in a more reassured manner.

Finally in our study, we assessed several the effect of covariates that were
not evaluated in literature previously, which may help in understanding
different risk factors for mesh-related complications and improve patients
counseling for synthetic sling placement. This is important in the current
view of the multiple FDA notifications and ongoing lawsuits in US and
Canada.

Our study was limited by the following: first, outcome was measured by
surgical intervention, so we only documented mesh-related complications
that were treated via surgical intervention. Thus, we likely underestimated
complications related to mesh that were treated conservatively. Second, we
could not identify type or severity of incontinence before primary surgery in
order to study its possible relationship with reoperation rate and its risk.
Third, there was no information about different types of surgical kits that
were used in sling implant, and different surgical techniques like retropubic
or transobturator placement of the sling could not be identified. So, their
presumed effect on the incidence rate of reoperation for mesh-related
complication could not be evaluated. Fourth, detailed reasons for which
slings were removed or excised were not available in all patient’ data. This
was due to the nature of coding system for surgical procedures.
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5.4 Future Research
Our study found no difference between urologists and gynecologists in
reoperation for complications after synthetic sling placement for SUI, which
is a common entity that is treated by both specialties. This might be the basis
for further studies and evaluation of other common surgical practice, which
can facilitate mutual training program that can accept candidates from both
specialties with focusing on procedure-based surgical skills rather than their
unique daily practice.

The effect of certain rare variables on reoperation after synthetic sling
placement needs more evaluation on. Multicentric assessment for example
can overcome the rarity of such variables and can provide more
comprehensive information on them.

Finally, academic and teaching hospitals play an important role in training
clinicians and equip different medical, regional, and local community
hospitals with surgeons who should be ready to practice independently. For
this, we think that further studies of different processes of care in teaching
hospital is vital at all dimensions, in order not to compromise health care
provided to population in our pathway of training future providers.
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Appendix A: List of Abbreviation

AIDS

Acquired Immune Deficiency Syndrome

BMI

Body Mass Index

CCI

Canadian Classification of health Intervention

CI

Confident Interval

CIHI

Canadian Institute for Health Information

CJD

Creutzfeldt-Jakob Disease

DAD

Discharge Abstract Database

DM

Diabetes Mellitus

FDA

Food and Drug Administration

HIV

Human Immunodeficiency Virus

HR

Hazard Ratio

ICD

International Classification of Diseases

ICES

Institute for Clinical Evaluative Sciences

ICS

International Continence Society

IQR

Interquartile range

ISD

Intrinsic Sphincteric Dysfunction

IUGA

International Urogynecological Association

LUTS

Lower Urinary Tract Symptoms

MAUDE

Manufacturer and User Device Experience

MUS

Midurethral Sling

OAB

Overactive Bladder

OHIP

Ontario Health Insurance Plan

POP

Pelvic Organ Prolapse

PVS

Pubovaginal Sling
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RMUS

Retropubic Midurethral Sling

SDM

Standardized difference of the mean

SDS

Same Day Surgery

SIS

Small Intestine Submucosa

SUI

Stress Urinary Incontinence

TMUS

Transobturator Midurethral Sling

TOT

Transobturator Tape

TVT

Tension-free Vaginal Tape

UDS

Urodynamic Study

US

United States

UTI

Urinary Tract Infection
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Appendix B

CCI Codes Used in Identifying Synthetic (Mesh-Based) SUI Procedures
in OHIP and CIHI-DAD/SDS Databases (Cohort Patients)
CCI Code

Dates

Description

Active

Number
of
patients
in cohort

1PL74AFFF

April

Fixation, bladder neck combined

2002-

open abdominal and endoscopic

March

transvaginal approach using

2006

2913

tension free vaginal tape [TVT]
technique

1PL74AFXXN

April

'Fixation, bladder neck

2002-

combined per orifice (vaginal)

Present

and open (abdominal) approach

3677

using synthetic material
1PL74AFXXQ

April

'Fixation, bladder neck

2003-

combined per orifice (vaginal)

Present

and open (abdominal) approach

66

using combined sources of tissue
[e.g. graft and synthetic tissue]
1PL74ALFF

April

Fixation, bladder neck combined

2002-

percutaneous and vaginal

March

approach using tension free

2006

vaginal tape [TVT] technique
83

11535

CCI Code

Dates

Description

Active

Number
of
patients
in cohort

1PL74ALXXN

April

Fixation, bladder neck combined

2006-

per orifice (vaginal) and

Present

percutaneous approach using

32268

synthetic material (e.g. TVT
technique)
1PL74CRXXN

April

'Fixation, bladder neck per

2009-

orifice (vaginal) approach with

Present

incision using synthetic tissue

7932

(e.g. TVT technique)
1PL74DAXXN

April

'Fixation, bladder neck

2009-

endoscopic (laparoscopic)

Present

(retropubic) approach using

549

synthetic tissue
1PL74LAXXN

1PL74LAXXQ

April

Fixation, bladder neck open

2006-

(retropubic, perineal) approach

Present

using synthetic material (sling)

April

Fixation, bladder neck open

2006-

(retropubic, perineal) approach

Present

using combined sources

84

933
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Appendix C

CCI Codes Used to Define Primary Outcome
CCI Code

Dates

Description

Active
1PL54CAXXN

April

Management of internal device, bladder neck

2006-

of synthetic urethral sling (tension free

Present

vaginal tape [TVT]) using per orifice
[vaginal] approach

1PL54LAXXN

April

Management of internal device, bladder neck

2006-

of synthetic material (urethral sling) (tension

Present

free vaginal tape [TVT]) using open
approach

1PL55CAXXN

1PL55LAXXN

1PQ56BA

1PQ56CA

April

Removal of device, bladder neck of synthetic

2006-

urethral sling [tension free vaginal tape]

Present

using vaginal approach

April

Removal of device, bladder neck of synthetic

2006-

urethral sling [tension free vaginal tape]

Present

using open approach

April

Removal of foreign body, urethra using

2002-

endoscopic per orifice (transurethral)

Present

approach

April

Removal of foreign body, urethra using per

2002-

orifice approach

Present
1PQ56DA

April

Removal of foreign body, urethra using
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CCI Code

Dates

Description

Active
2002-

endoscopic (percutaneous) approach

Present
1PQ56LA

April

Removal of foreign body, urethra using open

2002-

approach (abdominal, perineal)

Present
1PQ56QY

April

Removal of foreign body, urethra using open

2002-

transvaginal approach

Present
1PQ57BAGX

1PQ57LAAM

April

Extraction, urethra using endoscopic per

2002-

orifice approach (transurethral) and device

Present

NEC [e.g. forceps, meatome]

April

Extraction, urethra using open approach and

2002-

basket device

Present
1PQ57LAGX

April

Extraction, urethra using open approach and

2002-

device NEC [e.g. forceps, meatome]

Present
1PQ59BAAG

April

Destruction, urethra endoscopic per orifice

2002-

approach using laser

Present
1PQ59BAAZ

April

Destruction, urethra endoscopic per orifice

2002-

approach using ultrasonic probe

Present
1PQ72AC

April

Release, urethra using combined open
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CCI Code

Dates

Description

Active
2002-

abdominal with vaginal approach

Present
1PQ72LA

April

Release, urethra using open approach

2002Present
1PQ72PK

April

Release, urethra using open retropubic

2002-

approach

Present
1PQ72QY

April

Release, urethra using open transvaginal

2009-

approach

Present
1PQ72QYAG

April

Release, urethra using open transvaginal

2002-

approach and laser

Present
1PQ86MB

April

Closure of fistula, urethra simple excision

2002-

and closure terminating at skin

Present

(urethrocutaneous, urethroscrotal,
urethroperineal)

1PQ86MD

April

Closure of fistula, urethra NEC simple

2002-

excision and closure terminating in genital

March

tract [urethrovaginal]

2009
1PQ86MH**

April

Closure of fistula, urethra simple excision

2009-

and closure terminating in genital tract
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CCI Code

Dates

Description

Active

1RS55CAXXN

1RS55LAXXN

Present

[urethrovaginal]

April

Removal of device, vagina of synthetic

2003-

material (e.g. mesh, sling) using per orifice

Present

approach

April

Removal of device, vagina of synthetic tissue

2002-

(e.g. mesh) using open approach

Present
1RS56CA

1RS56CR

1RS56DA

April

Removal of foreign body, vagina using per

2002-

orifice [vaginal] approach (for simple

Present

extraction)

April

Removal of foreign body, vagina using per

2002-

orifice [vaginal] approach and incisional

Present

technique

April

Removal of foreign body, vagina using

2006-

endoscopic (laparoscopic) approach

Present
1RS56LA

April

Removal of foreign body, vagina using open

2006-

(abdominal) approach

Present
1RS86LAXXE

April

Closure of fistula, vagina NEC terminating at

2002-

skin, using open (perineal) approach and

March

local flap repair

2006
1RS86MB

April

Closure of fistula, vagina for fistula
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CCI Code

Dates

Description

Active

1SZ55LAXXN

2006-

terminating at skin (vaginal, perineal) and

Present

simple apposition (suturing) for closure

April

Removal of device, soft tissue of the chest

2002-

and abdomen of mesh using open approach

Present
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Appendix D

CCI Codes Used to Identify Study Covariates
Covariate
Obesity

Source

Codes

OHIP

E676, E010

CIHI-

E66x Obesity

DAD/SDS
(ICD 10)

278.x Obesity

CIHIDAD/SDS
(ICD 9)
Pelvic

CIHI-

82.40 Anterior & Posterior repair

organ

DAD/SDS

82.41 Anterior repair

prolapse

(CCP*)

82.42 Posterior repair

repair

82.43 Anterior & Posterior Repair

(with or

81.30 Repair of uterine support

without

81.31 Interposition

mesh)

81.32 Other uterine suspension
81.33 Vaginal repair chronic uterine inversion
81.39 Other repair of uterine support

Pelvic

CIHI-

1RS80CRXXN Synthetic repair vagina

organ

DAD/SDS

(Vaginal approach)

prolapse

(CCI)

1RS80CAXXN Synthetic repair vagina

repair

1RS80LAXXN Synthetic repair vagina,

(with

(abdominal approach)

mesh)

1RS80DAXXN Synthetic repair vagina (MIS

90

Covariate

Source

Codes
approach)
1RS80CRXXQ Repair vagina combined
source
1RS80CAXXQ Repair vagina combined
source
1RS80LAXXQ Repair vagina retropubic
combined tissue source
1RS74CRXXN Repair vagina with synthetics
1RS74LAXXN Abdominal repair vagina with
synthetics
1RS74DAXXN Repair vagina synthetics Lap
1RS74CAXXN Fixation vaginal approach
with mesh

Any

OHIP

S716 S717 S718 S719 S723 S720 S721 S722
S812 S760 S813 S761 S758 S759

prolapse
repair
CIHI-

1RS74 Fixation vagina

DAD/SDS

1RS80 Repair vagina

(CCI)
CIHI-

82.40 Anterior & Posterior repair

DAD/SDS

82.41 Anterior repair

(CCP)

82.42 Posterior repair
82.43 Anterior & Posterior Repair
81.30 Repair of uterine support
81.31 Interposition
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Covariate

Source

Codes
81.32 Other uterine suspension
81.33 Vaginal repair chronic uterine inversion
81.39 Other repair of uterine support

Prior

CIHI-

71.40 Suprapubic sling operation

possible

DAD/SDS

71.60 Periurethral suspension and

mesh based (CCP)

compression

SUI
procedure
Urologic

OHIP

A353, C353, C354, A354

visit
Gynecologi

OHIP

A205 A206 A203 A204 C205 C206 C203
C204 W305 W306

c visit
Hysterecto

A355, C355, W355, A356, C356, W356,

OHIP

S757 S816 S763 S762 S710 S758 S759

CIHI-

5CA89CK Vaginal Hysterectomy with

DAD/SDS

pregnancy

(CCI)

5CA89GB MIS hysterectomy with pregnancy

my

5CA89WJ Open hysterectomy with pregnancy
5CA89WK Open hysterectomy with
pregnancy
5MD60KE Cesarean section hysterectomy
5MD60RC Cesarean section hysterectomy
with forceps
5MD60RD Cesarean section hysterectomy
with vacuum
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Covariate

Source

Codes
1RM89 Total hysterectomy
1RM91 Radical hysterectomy

CIHI-

86.42 Hysterectomy with pregnancy

DAD/SDS

80.30 Total abdominal hysterectomy

(CCP)

80.40 Vaginal hysterectomy
80.50 Radical hysterectomy
80.60 Radical vaginal hysterectomy

High risk

CIHI-

1PQ86MH Urethrovaginal fistula excision and

mesh

DAD/SDS

closure

patient:

(CCI)

1PQ86MD Urethrovaginal fistula excision and

Prior

closure

fistula

1PQ86MB Urethral fistula excision and
closure
1RS86MB Vaginal fistula closure
1RS86CAXXE Vaginal fistula closure
1RS86LAXXE Vaginal fistula closure
OHIP

S709A, S523A, S524A

CIHI-

70.33 Closure of fistula to urethra

DAD/SDS
(CCP)
High risk

CIHI-

mesh

DAD/SDS

patient:

(CCI)

1PQ87QY Partial excision urethra

Prior
urethral
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Covariate

Source

Codes

diverticulu
m
CIHI-

70.20 Excision or destruction of urethral

DAD/SDS

lesion

(CCP)

82.52 Vaginal reconstruction diverticulum

OHIP

S541

High risk

CIHI-

1PQ27JA Radiation urethra, external beam

mesh

DAD/SDS

1PM27JA Radiation bladder, external beam

patient:

(CCI)

1RM26 Radiation uterus, brachytherapy

Prior

1RM27JA Radiation uterus, external beam

radiation

1RZ27JA Radiation female genital tract

therapy

1RN26 Radiation cervix, brachytherapy
1RN27 Radiation cervix, external beam
1NQ27JA Radiation rectum, external beam
1NT26CA/HA/LA Radiation anus,
brachytherapy
1NT27JA Radiation anus, external beam
1RB27JA Radiation ovary, external beam
1RS26 Radiation vagina, brachytherapy
1RS27JA Radiation vagina, external beam

High risk

CIHI-

mesh

DAD/SDS

patient:

ICD10

S37.3 Injury of urethra

Prior
urethral
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Covariate

Source

Codes

injury
CIHI-

867.0 Injury bladder or urethra

DAD/SDS

867.1 Open injury bladder or urethra

ICD9
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